The US myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 6.4% during the forecast period. The US contributes significantly to the growth of the MI treatment market in North America. The increasing prevalence of heart diseases, high per capita healthcare expenditure and well-developed healthcare infrastructure are the key factors to promote the growth of the myocardial infarction treatment market in the US. The US is expected to make a major contribution to the MI treatment market due to the rise in the adoption of hybrid operating rooms and innovative treatment technology. Hospitals and clinics in the US are well equipped with the latest treatment devices which are essential to perform critical MI surgeries. Cleveland Clinic, Mayo Clinic, New York-Presbyterian University Hospital of Columbia and Cornell are some of the key hospitals contributing to the growth of the MI treatment market. In 2019, the average cardiology procedures which include bypass surgery ranges from $56,000 to $200,000 in the US. The cost of heart valve replacement surgery costs around $80,000- $200,000. Additionally, various physical therapies followed by surgery may cost around $50-$350 per session, according to the Center for Medicare & Medicaid Services.

A full Report of US Myocardial Infarction Market at https://www.omrglobal.com/industry-reports/us-myocardial-infarction-market

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

Request a Free Sample of Report on US Myocardial Infarction Market @ https://www.omrglobal.com/request-sample/us-myocardial-infarction-market

US Myocardial Infarction Market Segmentation

By Type

• Non-ST-elevation myocardial infarction (NSTEMI)
• ST-elevation myocardial infarction (STEMI)
• Silent Heart Attacks

By Device

• Left Ventricular Assist Device (LVAD)
• Pacemaker
• Catheters
• Implantable Cardioverter-Defibrillator (ICD)
• Others (Stent Graft)

By Diagnosis

• Electrocardiography (ECG)
• Chest X-Ray
• Computed Tomography (CT Scan)
• Echocardiography
• Others (Blood Test)

By Treatment

• Medication
• Surgery

By End-User

• Hospital & Clinics
• Ambulatory Surgical Centers
• Research Institutes

Regional Analysis

• China
• Japan
• India
• Rest of Asia-Pacific

Company Profiles

• Abbott Laboratories Inc.
• AstraZeneca PLC
• Bayer AG
• Boston Scientific Corp.
• Bristol-Myers Squibb Co.
• CSL Ltd.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Merck KGaA
• Mesoblast Ltd.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Siemens AG

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404